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Background: Few reports discuss the outcome of pulmonary metastasis after radical esophagectomy for
esophageal cancer. To clarify the data from such cases, we conducted a retrospective study on the clinical outcome
of patients who developed pulmonary metastasis after undergoing radical esophagectomy.
Methods: We retrospectively reviewed the prognosis and clinical outcome of 25 patients who developed
metachronous pulmonary metastasis after esophagectomy for esophageal cancer.
Results: The site of recurrence was pulmonary without extrapulmonary metastasis in 14 patients and
extrapulmonary metastasis was observed in 11. Nineteen patients had multiple pulmonary metastasis and 6 had
solitary pulmonary metastasis. Twenty-four of patients underwent systemic chemotherapy during initial treatment
for metastatic lesions. Pulmonary metastasectomy was indicated in 5 patients with solitary metastasis. The actual
1-, 2- and 4-year survival rates were 60%, 36% and 27%, respectively. Gender, operative procedure, and
postoperative morbidity were not significant prognostic factors. However, pathological staging of primary
esophageal cancer was a significant prognostic factor. Survival was significantly worse in patients who did not
undergo resection than in those who did. The number of pulmonary metastasis, complicated extrapulmonary
metastasis and the time of recurrence were also significant prognostic factors.
Conclusions: Multiple pulmonary metastases or complicated extrapulmonary metastasis were unfavorable
prognostic factors for patients with pulmonary metastasis arising from esophageal cancer. Although, surgical
intervention is not recommended in such cases, metastasectomy is an acceptable choice of treatment for solitary
pulmonary metastasis.
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Esophageal cancer is a highly lethal disease, and one
of the most common neoplasms. Recent advances in
multimodal treatment, including esophagectomy with
three-field lymph node dissection and definitive chemor-
adiotherapy, have improved the prognosis of patients
with esophageal cancer [1-3]. Particularly, patient sur-
vival after esophagectomy with three-field lymph node
dissection is better than that after the two-field pro-
cedure [4]. However, the disease recurs after radical* Correspondence: mtake@hyo-med.ac.jp
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reproduction in any medium, provided the oresophagectomy in 30%-50% patients with hematogenous
recurrence accounting for 50% of these cases [5-7].
Hematogenous metastases are commonly found in the
liver, bones and lungs [6,7]. However, few reports discuss
the outcome of pulmonary metastasis after radical eso-
phagectomy for esophageal cancer [8,9]. To clarify the
data from such cases, we conducted a retrospective
study on the clinical outcome of patients who developed
pulmonary metastasis after undergoing radical esopha-
gectomy at our department.Methods
We retrospectively analyzed patients who developed
metachronous pulmonary metastasis after undergoingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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General Hospital, Osaka Japan between January 2000
and March 2010. During this period, 373 patients with
esophageal cancer have been underwent radical esopha-
gectomy with reconstruction. All patients underwent
complete radical resection for primary esophageal
cancer. After surgery, patients were monitored on an
outpatient basis at 3-month intervals for 2 years, and at
6-month intervals thereafter (Additional file 1: Table S1).
No patients died during the initial hospital stay or within
1 month of surgery after surgery. Of these 373 patients,
25 (6.7%) were diagnosed with metachronous pulmonary
metastasis after esophagectomy. Recurrent disease was
frequently diagnosed by chest X-rays, tumor markers, or
computed tomography and occasionally by positron
emission tomography. Further examinations were also
performed to diagnose extrapulmonary metastases. The
last follow-up data for this study population was gath-
ered in January 2011, and the median follow-up duration
was 29.2 months (range: 5–124 months).
The therapeutic approach to each metastasis was
selected by individual surgeons. This was solely done
on the basis of their knowledge and experience, and
not any preset common criteria, institutional protocols
or guidelines. Treatment options for pulmonary metas-
tasis included best supportive care, systemic chemo-
therapy, and pulmonary metastasectomy. The selection
criteria of pulmonary metastatectomy from esophageal
carcinoma were as follows; 1) the patient has a per-
formance status (PS) of 0 or 1 based on ECOG scale,
2) patient can tolerate surgical intervention, 3) the
metastasic lesion was diagnosed as solitary metastasis
without pleural dissemination, 4) there are no meta-
static lesions other than lung lesion. Resected speci-
mens were referred to the department of pathology in
our department by at least 2 experienced pathologists.
A pulmonary lesion was diagnosed as a metastasis
from esophageal cancer on histological findings as fol-
lows; a similarly to the primary esophageal tumor; a
tumor progression originating from the bronchial sube-
pithelium; and/or a discontinuity between the tumor
and bronchial epithelium.
We gathered the following perioperative demo-
graphic and clinical data from patient records: age,
gender, chest / abdominal surgical procedure, type of
recurrence, and treatment following diagnosis with
pulmonary metastasis. Furthermore, we evaluated the
depth of invasion, extent of lymph node metastases, lymph-
atic and venous invasion, and the pathological diagnosis
and classification of primary esophageal cancer using the
TNM classification given by the Union for International
Cancer Control [10] and the Japanese classification of
esophageal cancer given by the Japanese Society for
Esophageal Diseases [11].The following clinicopathological factors were ana-
lyzed for prognostic significance using the Kaplan-Meier
method and log-rank test; age, gender, initial surgical
procedure, location of esophageal tumor, pattern of re-
currence, tumor classification, depth of tumor invasion,
extent of lymph node metastasis, pathological staging,
lymphatic and venous invasion of the primary tumor,
number of pulmonary metastatic lesions, time of recur-
rence, and presence or absence of pulmonary resection
for metastatic lesions. P < 0.05 was considered statisti-
cally significant. Statistical analysis was performed using
statistical analysis program package (SPSS 11.0; SPSS
Inc., Chicago, Illinois, USA). This study was conducted
in accordance with institutional guidelines of the Ethics
Committee for Clinical Rresearch of Osaka City General
Hospital.
Results
The clinical characteristics of patients are summarized
in Additional file 2: Table S2. There were 21 men and 4
women with a mean age of 65.7 years (range 48–75) at
the time of esophagectomy. Twenty-one patients under-
went thoracoscopic esophagectomy, and 4 underwent
esophagectomy via thoracotomy. An abdominal ap-
proach using laparoscopy was adopted in 19 patients
and a gastric roll was used as an esophageal substitute in
22 patients. All patients underwent complete resection
for the primary esophageal lesion (R0). Pathological
TNM stages of the primary esophageal cancer were as
follows; stage IA in 4 patients (17%); IIA in 3 (13%); IIB
in 2 (8%); IIIA in 6 (24%); IIIB in 6 (24%); and IIIC in 4
(17%). Tumor classifications included as follows; squa-
mous cell carcinoma in 20 patients, adenocarcinoma in
4, and basaloid squamous cell carcinoma in 1. Seventeen
patients (68%) exhibited lymph node metastasis. Lymph-
atic invasion was diagnosed in 10 patients, and venous
was diagnosed in 4. Time of recurrence after initial
surgery was as follows; ≦2 years in 16 patients (64%)
and > 2 years in 9 (36%). Site of recurrence was only
pulmonary metastases in 14 patients, and extrapulmon-
ary metastasis was observed in 11 patients (lymph node
metastasis in 3, other hematogenous metastases in 7,
and complicated metastasis in 1). Nineteen patients had
multiple pulmonary metastases and 6 had solitary pul-
monary metastasis. Twenty-four of patients underwent
systemic chemotherapy during initial treatment for
metastatic lesions. Pulmonary metastasectomy was indi-
cated in 5 patients with solitary metastasis; the clinico-
pathological data of primary esophageal cancer in these
5 patients are summarized in Table 1. Three patients
were diagnosed with upper thoracic esophageal cancer
and 2 with lower thoracic esophageal cancer. Lymph
node metastasis was histologically diagnosed in 2
patients, while lymphatic invasion was positive in 1. The
Table 1 Clinicopathological data on initial esophageal cancer in metastasectomy patients
Case Gender Age Tumor location pT pN 1y v Pathology
1 M 57 Upper thoracic pT1b pN0 0 0 SCC
2 M 58 Upper thoracic pT3 pN0 0 0 SCC
3 M 74 Lower thoracic pT3 pN1 + 0 SCC
4 F 63 Lower thoracic pT1b pN1 0 0 Basaloid
5 M 75 Upper thoracic pT1b pN0 0 0 SCC
ly: lumphatic invasion.
v: venous invasion.
PS: ECOG performance status.
SCC: Squamous cell carcimona.
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mucosal in 3. All 5 patients with metastasectomy had a
good performance status and underwent combined
chemotherapy with 5-fluorouracil and cisplatin before
metastasectomy (Table 2). All patients underwent wedge
resection. None died as a result of metastasectomy, and
all were discharged without recurrent disease. Only 1
patient received chemotherapy after metastasectomy,
this patient died of multiple metastatic tumors 6 months
after metastasectomy. Four patients are currently alive,
without any evidence of metastatic disease, 124, 65, 48
and 32 months after esophagectomy, respectively.
Patient survival according to prognostic factors is
shown in Table 3. The actual 1-, 2- and 4-year survival
rates were 60%, 36% and 27%, respectively. Gender, op-
erative procedure, and postoperative morbidity were not
significant prognostic factors. However, pathological sta-
ging of the primary esophageal cancer was a significant
prognostic factor. The actual 1- and 4-year survival rates
were 66.7% and 53.5% for stage I or II, respectively, and
56.3% and 12.5% for stage III or IV, respectively. Lymph-
atic and venous invasion were not significant factors.
Survival was significantly worse in patients who did not
undergo resection than in those who did. Number of
pulmonary metastasis lesions (solitary versus multiple),
extrapulmonary metastasis and time of recurrence were
also significant prognostic factors.
Discussion
In Japan, radical esophagectomy with three-field lympha-
denectomy is recommended as the first line of treatmentTable 2 Clinical data on pulmonary metastases in metastasec
Case Gender PS CT pre/post
metastasectomy
1 M 0 Yes/No
2 M 0 Yes/No
3 M 0 Yes/No
4 F 0 Yes/No
5 M 0 Yes/No
CT: chemotherapy.for locally advanced esophageal cancer [1,2,4]. However,
the recurrence rate of esophageal cancer is high even
after radical esophagectomy [1,2,4,5]. Nakagawa et al. [7]
reported an overall 5-year survival rate of 55.6% after
three-field lymph node dissection. In this study, recur-
rence was most frequently locoregional followed by after
hematogenous recurrence. Kunisaki et al. [6] also
reviewed patients with tumor recurrence after curative
esophagectomy, and reported that the tumors recurred
in 43.4% patients, and almost all cases recurred within 2
years after surgery (88.9%). Moreover, the survival of
patients with distant metastasis was significantly worse
than that of patients with locoregional recurrence. In
these reports, the prognosis of the patients with
hematogenous recurrence was poor despite aggressive
multimodal treatment.
Law et al. [5] reported on the site of recurrence in 56
patients who underwent curative resection. Recurrence
was most frequent in the lungs (13/56), followed by the
liver (11/56). Mafune et al. [10] reviewed autopsy find-
ings in 69 patients with esophageal cancer (33 of whom
had underwent resection, whereas 36 did not). The liver
and lungs were the most common sites of hematogenous
metastasis. A high incidence of hematogenous metasta-
sis suggests that stronger chemotherapy is required, irre-
spective of resection. In our study, 24 patients were
treated with systemic chemotherapy for pulmonary me-
tastasis; the disease persisted in only 1 patient after
chemotherapy. It is important to develop effective che-
motherapeutic regimens to improve the outcome and
prognosis of such cases. We previously reported thetomy patients
Operative procedure OS Survival
Wedge resection 1305 Dead
Wedge resection 1938 Alive
Wedge resection 2599 Alive
Wedge resection 4024 Alive
Wedge resection 1260 Alive
Table 3 Survival rate according to clinicopathological factors
Factors related survival n survival rate
1 year 2 year 4 year p value
All cases 25 60.0 36.0 27.5
Gender Male 21 57.1 28.6 22.9 0.424
Female 4 75.0 75.0 50.0
Thoracic procedure Thoracotomy 21 75.0 50.0 50.0 0.402
Thoracoscopy 4 57.1 33.3 22.2
Postoperative morbidity Present 11 72.7 45.5 36.3 0.162
Absent 14 50.0 28.6 21.4
pT pT1 8 75.0 50.0 33.3 0.562
pT3, pT4 17 52.9 29.4 23.5
pN + 18 61.1 27.8 22.2 0.707
- 7 57.1 57.1 38.1
pStage I, II 9 66.7 66.7 53.3 0.042
III, IV 16 56.3 18.8 12.5
Classification of the tumor Squamous cell csrcinoma 20 50.0 25.0 18.8 0.052
Other type 5 80.0 80.0 60.0
Lymphatic invasion + 10 44.4 11.1 11.1 0.218
- 15 68.8 50.0 36.4
Venous invasion + 4 50.0 0 0 0.290
- 21 61.9 42.9 32.1
Number of pulmonary metastasis Solitary 6 100.0 100.0 80.0 0.001
Multiple 19 47.4 15.8 10.5
Extrapulmonary metastasis Present 11 45.8 18.2 0 0.016
Absent 14 71.4 50.0 41.7
Pulmonary resection Resected 5 100.0 100.0 75.0 0.002
Nonresected 20 50.0 20.0 15.0
Time of recurrence Within 2 year 16 37.5 0.0 0.0 0.001
More than 2 years 9 100.0 100.0 76.2
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geal cancer tissue [11], thus supporting the use of this
chemotherapeutic agent against esophageal cancer.
To date, few reports have discussed the surgical treat-
ment of pulmonary metastasis arising from esophageal
cancer [8,9,12]. As hematogenous recurrence of esopha-
geal cancer is considered a systemic disease, surgical
treatment is rarely indicated. Ichikawa et al. [9] reviewed
23 patients who underwent surgical treatment for meta-
chronous pulmonary metastasis arising from esophageal
cancer. They concluded that surgical intervention for
metachronous pulmonary metastasis is an acceptable
treatment option in select cases without extrapulmonary
metastasis. In our patients, the 1- and 2-year survival
rates of patients who did not undergo resection were
50% and 20%, respectively; these rates were significantlyworse those of patients who underwent resection. Me-
dian survival time from esophagectomy was 366.5 days
for patients who did not undergo resection; conversely,
75% patients who undergo resection survived for 2 years.
As the number of cases who underwent resection was
limited, no definite conclusions could be drawn from
our study results. However, our case series suggests that
surgical intervention for metastatic lesions arising from
esophageal cancer is indicated when metastases are tech-
nically resectable and patients have a good performance
status.
Conclusion
In conclusions, multiple pulmonary metastases or compli-
cated extrapulmonary metastasis were unfavorable prog-
nostic factors for patients with pulmonary metastasis from
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recommended in such cases, metastasectomy for solitary
pulmonary metastasis is an acceptable treatment choice.
To overcome the limitations of a small case series, further
studies of patients with pulmonary metastasis arising from
esophageal cancer are necessary to determine the selec-
tion criteria for surgical intervention.Additional files
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